Skip to main content

Table 1 Summary of Kaplan-Meier estimates for 2-year OS and 2-year EFS for clinically high-risk patients using each of the 18 proposed models

From: Predicting survival times for neuroblastoma patients using RNA-seq expression profiles

   LPS    non-LPS     
Outcome Prob SE N Prob SE N Data Model P-value
OS 0.57 0.09 31 0.79 0.05 59 Null model   0.574
OS 0.60 0.07 57 0.91 0.05 33 G 1 0.081
OS 0.60 0.06 60 0.93 0.05 30 G 2 0.082
OS 0.55 0.09 29 0.79 0.05 61 G 3 0.166
OS 0.50 0.10 24 0.79 0.05 66 G 4 0.164
OS 0.57 0.07 55 0.94 0.04 35 T 1 0.128
OS 0.56 0.07 47 0.88 0.05 43 T 2 0.002
OS 0.41 0.12 17 0.78 0.05 73 T 3 0.048
OS 0.57 0.09 33 0.79 0.05 57 T 4 0.081
OS 0.61 0.07 56 0.88 0.06 34 I 1 0.124
OS 0.51 0.08 36 0.85 0.05 54 I 2 0.027
OS 0.47 0.10 25 0.81 0.05 65 I 3 0.137
OS 0.43 0.10 25 0.82 0.05 65 I 4 0.017
OS 0.57 0.07 56 0.94 0.04 34 TI 1 0.092
OS 0.54 0.07 49 0.90 0.05 41 TI 2 0.001
OS 0.40 0.11 21 0.81 0.05 69 TI 3 0.036
OS 0.40 0.11 22 0.80 0.05 68 TI 4 0.009
OS 0.42 0.10 25 0.82 0.05 65 Ensemble   0.016
EFS 0.39 0.08 37 0.36 0.07 53 Null model   0.616
EFS 0.35 0.07 53 0.39 0.08 37 G 1 0.299
EFS 0.34 0.07 52 0.41 0.08 38 G 2 0.266
EFS 0.30 0.06 58 0.50 0.09 32 G 3 0.125
EFS 0.31 0.06 59 0.48 0.09 31 G 4 0.125
EFS 0.29 0.06 62 0.56 0.10 28 T 1 0.036
EFS 0.35 0.07 51 0.40 0.08 39 T 2 0.946
EFS 0.29 0.07 38 0.43 0.07 52 T 3 0.065
EFS 0.31 0.07 47 0.43 0.08 43 T 4 0.150
EFS 0.35 0.06 66 0.43 0.10 24 I 1 0.256
EFS 0.35 0.06 66 0.43 0.10 24 I 2 0.256
EFS 0.29 0.07 43 0.45 0.07 47 I 3 0.052
EFS 0.29 0.07 42 0.44 0.07 48 I 4 0.082
EFS 0.31 0.06 57 0.47 0.09 33 TI 1 0.084
EFS 0.33 0.06 68 0.50 0.11 22 TI 2 0.183
EFS 0.29 0.07 42 0.45 0.07 48 TI 3 0.062
EFS 0.30 0.07 44 0.44 0.08 46 TI 4 0.085
EFS 0.36 0.06 58 0.39 0.09 32 Ensemble   0.599
  1. Patients with predicted survival of less than 2 years are labeled as Low Predicted Survival (LPS), and otherwise are non-LPS. Columns labeled “Prob.”, “SE”, and “N” correspond to the estimated probability of 2-year survival, the standard error of the estimate, and the number of patients in the given cohort. The P-values are for the logrank test comparing LPS to non-LPS survival. The “Data” column refers to the type of RNA-seq data used, and the “Model” column refers to the dimension reduction technique used